Activity 1: Are You Missing PBC?

Target Audience

The educational design of this activity addresses the needs of gastroenterology and hepatology specialist physicians, nurse practitioners (NPs), and physician associates (PAs) who are involved in managing patients with primary biliary cholangitis (PBC), as well as a broader audience of front-line treaters who are in a position to identify patients with suspected PBC and refer them to specialist care (primary care and internal medicine physicians, NPs, PAs).

Program Overview

The first activity of this series, titled PBC Powerlifting: Are You Missing PBC?, is intended to strengthen your expertise in the identification and diagnosis of PBC. Dr. Nancy Reau will walk you through her approach to discussing important aspects of disease management with your patients, including how to best engage patients in their therapeutic planning and overcome barriers to successful long-term outcomes.

Educational Objectives

After completing this activity, the participant should be better able to:

1. Describe the pathophysiology of PBC as well as its symptom manifestations among diverse patient populations
2. Implement appropriate assessment strategies to diagnose PBC early within the disease course
3. Educate patients on their disease and what to expect for management, including psychosocial aspects and available treatment options

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

The American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) Recognition Statement

• Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
• For ABIM MOC points, your information will be shared with the ABIM through Integritas’ Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
• By sharing your Diplomate Board ID # and DOB, you are giving Integritas Communications permission to use this information/data to report your participation to these Boards via the PARS.

Integritas Contact Information

For more information about the approval (ACCME credit) of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 75% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas and Global Education Group adhere to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty has the following relevant financial relationships with ineligible companies:

Nancy S. Reau, MD: Consulting Fees: Arbutus Biopharma, Gilead Sciences, Inc., Salix Pharmaceuticals, Inc., Vir Biotechnology, Inc.; Contracted Research: AbbVie, Gilead Sciences, Inc.

The planners and managers at Integritas Communications and Global Education Group have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas and Global do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.